Legal
Judges Dismissed 5 FCPA Cases Over DOJ Misconduct in 26 Trials
Judge Howard Matz called it "an unusual and extreme picture of a prosecution gone badly awry.
Latest — Page 36
Deals
Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…
Deals
Aligos Sells China HBV Rights to Amoytop in $445M Deal
Aligos Therapeutics sold the Greater China rights to pevifoscorvir sodium to Fujian-based Amoytop for up to $445 million: $25 million upfront and $420…
Deals
Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win
Revolution Medicines is raising $2 billion in a stock offering priced at $142 per share, up from the $1 billion it announced Monday, hours after reporting…
Deals
Revolution Medicines Prices Record Raise, Biotech's Biggest Since Pandemic
Revolution Medicines just priced a public equity raise, the largest single biotech offering since the Covid-19 pandemic.
SEC
FDIC, OCC Bar Reputation Risk as Debanking Basis Starting June 6
The FDIC and OCC just banned reputation risk as a basis for bank supervision.
Legal
Seventh Circuit Frees 2 ComEd Execs, Orders New Trial
The Seventh Circuit Court of Appeals ordered two former Commonwealth Edison executives released from federal prison hours after oral arguments on the FCPA's…
Deals
Sold for $1.55B: Daiichi Sankyo's OTC Unit Goes to Suntory
Daiichi Sankyo sold its consumer health unit to Suntory Holdings for 246.5 billion yen, roughly $1.55 billion, in a staged transfer that kicks off this June…
Deals
Biogen Paid $5.6B for Apellis; Filing Confirms Deal Terms
Biogen paid $5.6B for Apellis, and a new SEC filing confirmed the deal details CEO Chris Viehbacher has been engineering: a company that doesn't grow on…
Deals
Bain Built $300M Beeline Medicines on 5 BMS Autoimmune Programs
Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty…
FDA
FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements
FDA cleared Foundayo, Eli Lilly's oral GLP-1 pill for obesity, on April 1, but the approval letter lists three postmarketing requirements tied to what the…
Legal
Cleared: Judge Hoyt Acquits Rovirosa in FCPA's 4th Post-Trial Win
Judge Kenneth Hoyt of the U.S. District Court for the Southern District of Texas dismissed the FCPA indictment against Ramon Alexandro Rovirosa Martinez…
Legal
Treasury Filed First GENIUS Act Rule on $10B Stablecoin State Oversight
Treasury filed its first proposed rule under the GENIUS Act, 12 C.F.R. Parts 1520–1521, setting the standard that determines whether a stablecoin issuer…
FDA
FDA Cleared Filspari for FSGS; Travere Eyes $3B U.S. Peak
FDA cleared Filspari for focal segmental glomerulosclerosis on Monday, handing Travere Therapeutics a fresh shot at what it values as a more than $3 billion…
FDA
Doubles PDAC Survival: Revolution Jumps 40% on Daraxonrasib Phase 3 Data
Revolution Medicines shares jumped to $134.80 Monday, up nearly 40%, after daraxonrasib delivered overall survival of 13.2 months in metastatic pancreatic…
